Drug Type Antibody-photosensitizer conjugates |
Synonyms- |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Brain Cancer | Phase 2 | United States | 01 Aug 2026 | |
| Squamous Cell Carcinoma of Head and Neck | Phase 2 | United States | 01 Aug 2019 | |
| Secondary malignant neoplasm of lung | Phase 2 | United States | 19 Jul 2018 | |
| Acoustic Neuroma | Phase 1 | United States | 01 Jul 2026 | |
| Glioblastoma | Phase 1 | United States | 01 Jul 2026 | |
| Meningioma | Phase 1 | United States | 01 Jul 2026 | |
| Pituitary Adenoma | Phase 1 | United States | 01 Jul 2026 |
Phase 1 | 14 | (Tumor-negative Lymph Nodes (by 18F-FDG Scan)) | rcqlsxakir = zpjrifecvc rcsleafujo (papdmuezxo, vjgguaycrq - zhethnzwts) View more | - | 19 May 2023 | ||
(Tumor-positive Lymph Nodes (by 18F-FDG Scan)) | rcqlsxakir = xxphnckfsk rcsleafujo (papdmuezxo, vjbtjircip - daibktcggm) View more | ||||||
Phase 2 | 3 | (T1 or T2 Stage and Node-negative) | uazwtalhyl = lvvshjyvyk drdrsglexb (wbfwqegcgs, rqytbfmcak - fgbekzgajj) View more | - | 10 Nov 2022 | ||
(Any T Stage and Node-positive) | uazwtalhyl = eycbqamioz drdrsglexb (wbfwqegcgs, qrqgqwmoif - sqyzauezoy) View more |





